Rosen Law Firm Investigates Simulations Plus for Potential Securities Fraud
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Source: PRnewswire
- Securities Fraud Investigation: The Rosen Law Firm is investigating potential securities claims against Simulations Plus (NASDAQ:SLP) for possibly issuing misleading business information, allowing affected shareholders to seek compensation without upfront costs.
- Significant Stock Drop: On July 15, 2025, Simulations Plus's stock plummeted by 25.75% after reporting third-quarter sales of $20.4 million, which fell short of the consensus estimate of $20.9 million, indicating persistent weak demand.
- Class Action Preparation: The firm is preparing a class action to recover investor losses, encouraging affected investors to join through their website or by phone, highlighting their commitment to protecting investor rights.
- Firm's Track Record: The Rosen Law Firm secured over $438 million for investors in 2019 and was ranked first by ISS Securities Class Action Services in 2017, demonstrating its strong capabilities and successful history in securities litigation.
Analyst Views on SLP
Wall Street analysts forecast SLP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLP is 19.00 USD with a low forecast of 19.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 20.770
Low
19.00
Averages
19.00
High
19.00
Current: 20.770
Low
19.00
Averages
19.00
High
19.00
About SLP
Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. It operates through two segments: software and services. The Company’s business units include cheminformatics, physiologically based pharmacokinetics, clinical pharmacology and pharmacometrics, quantitative systems pharmacology, adaptive learning & insights and medical communications. The Company operates in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. It delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Its cutting-edge technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
